MoneyWorks4Me

Beryl Drugs - Quaterly Results

12 Feb 2024 Evaluate
The sales is pegged at Rs. 76.60 millions for the December 2023 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 81.90 millions during the year-ago period.The Total revenue for the quarter ended December 2023 of  Rs. 3.10  millions  grew by 116.78% from Rs. 1.43 millions.Operating profit surged to 7.96 millions from the corresponding previous quarter of 7.15 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 76.60 81.90 -6.47 239.16 210.63 13.55 271.57 147.69 83.88
Other Income 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBIDT 7.96 7.15 11.33 26.49 19.40 36.55 22.14 5.73 286.39
Interest 1.13 1.17 -3.42 3.30 3.55 -7.04 4.16 4.37 -4.81
PBDT 6.83 5.98 14.21 23.19 15.85 46.31 17.98 1.36 1222.06
Depreciation 3.08 2.20 40.00 8.85 6.61 33.89 8.14 10.86 -25.05
PBT 3.75 3.78 -0.79 14.34 9.24 55.19 9.84 -9.50 -203.58
TAX 0.65 2.35 -72.34 3.17 2.21 43.44 2.18 -2.91 -174.91
Deferred Tax -0.46 2.35 -119.57 -1.94 2.21 -187.78 0.58 -3.00 -119.33
PAT 3.10 1.43 116.78 11.17 7.03 58.89 7.66 -6.59 -216.24
Equity 50.72 50.72 0.00 50.72 50.72 0.00 50.72 50.72 0.00
PBIDTM(%) 10.39 8.73 19.03 11.08 9.21 20.26 8.15 3.88 110.13
Peers
Company Name CMP
Sun Pharma. Inds. 1847.00
Dr. Reddys Labs. 1212.30
Cipla 1368.65
Lupin 2121.05
Zydus Lifesciences 1170.00
View more..